American journal of nuclear medicine and molecular imaging最新文献

筛选
英文 中文
Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF. SSRF大分子晶体束线2级生物安全性的实现。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Huating Kong, Minjun Li, Qin Xu, Huan Zhou, Feng Yu, Qisheng Wang
{"title":"Implementation of level-2 biosafety for a macromolecular crystallography beamline at SSRF.","authors":"Huating Kong,&nbsp;Minjun Li,&nbsp;Qin Xu,&nbsp;Huan Zhou,&nbsp;Feng Yu,&nbsp;Qisheng Wang","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Macromolecular crystallography is commonly used to determine the structure of biological macromolecules. Currently the beamlines at synchrotron radiation facilities play an important role in macromolecular crystallography, and have produced an enormous number of molecular structures to help solve scientific questions and support applications. Structure information makes significant contributions to the virus-related research as well. However, it is mandatory to be protected the operators under a compatible biosafety infrastructure when a pathological agent is set up in a beamline. Here a level-2 biosafety protection for a macromolecular crystallography beamline at Shanghai Synchrotron Radiation Facility (SSRF) is introduced. To fulfill the biosafety in a radioactive environment, a dedicated design is implemented. Since the beamline will be opened to the external users from nationwide research units, the management process and experimental method are also drawn up.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727877/pdf/ajnmmi0011-0529.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route. 回顾了近十年来利用177Lu靶向治疗癌症的进展:重点是通过直接中子活化途径产生的177Lu。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Rubel Chakravarty, Sudipta Chakraborty
{"title":"A review of advances in the last decade on targeted cancer therapy using <sup>177</sup>Lu: focusing on <sup>177</sup>Lu produced by the direct neutron activation route.","authors":"Rubel Chakravarty,&nbsp;Sudipta Chakraborty","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Lutetium-177 [T½ = 6.76 d; E<sub>β</sub> (max) = 0.497 MeV; maximum tissue range ~2.5 mm; 208 keV γ-ray] is one of the most important theranostic radioisotope used for the management of various oncological and non-oncological disorders. The present review chronicles the advancement in the last decade in <sup>177</sup>Lu-radiopharmacy with a focus on <sup>177</sup>Lu produced via direct <sup>176</sup>Lu (n, γ) <sup>177</sup>Lu nuclear reaction in medium flux research reactors. The specific nuances of <sup>177</sup>Lu production by various routes are described and their pros and cons are discussed. Lutetium, is the last element in the lanthanide series. Its chemistry plays a vital role in the preparation of a wide variety of radiopharmaceuticals which demonstrate appreciable <i>in vivo</i> stability. Traditional bifunctional chelators (BFCs) that are used for <sup>177</sup>Lu-labeling are discussed and the upcoming ones are highlighted. Research efforts that resulted in the growth of various <sup>177</sup>Lu-based radiopharmaceuticals in preclinical and clinical settings are provided. This review also summarizes the results of clinical studies with potent <sup>177</sup>Lu-based radiopharmaceuticals that have been prepared using medium specific activity <sup>177</sup>Lu produced by direct neutron activation route in research reactors. Overall, the review amply demonstrates the practicality of the medium specific activity <sup>177</sup>Lu towards formulation of various clinically useful radiopharmaceuticals, especially for the benefit of millions of cancer patients in developing countries with limited reactor facilities.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727880/pdf/ajnmmi0011-0443.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases: 15O positron emission tomography studies. 乙酰唑胺给药后测量脑血流的最佳时机,以检测双侧大脑大动脉狭窄闭塞性疾病患者先前存在的脑血流动力学和代谢:15O正电子发射断层扫描研究
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Masakazu Kobayashi, Suguru Igarashi, Tatsuhiko Takahashi, Shunrou Fujiwara, Kohei Chida, Kazunori Terasaki, Yoshitaka Kubo, Kuniaki Ogasawara
{"title":"Optimal timing for measuring cerebral blood flow after acetazolamide administration to detect preexisting cerebral hemodynamics and metabolism in patients with bilateral major cerebral artery steno-occlusive diseases: <sup>15</sup>O positron emission tomography studies.","authors":"Masakazu Kobayashi,&nbsp;Suguru Igarashi,&nbsp;Tatsuhiko Takahashi,&nbsp;Shunrou Fujiwara,&nbsp;Kohei Chida,&nbsp;Kazunori Terasaki,&nbsp;Yoshitaka Kubo,&nbsp;Kuniaki Ogasawara","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The present study determined the optimal timing of scanning for measurement of cerebral blood flow (CBF) after acetazolamide (ACZ) administration for detection of preexisting cerebral hemodynamics and metabolism in bilateral major cerebral artery steno-occlusive diseases. Thirty three patients underwent <sup>15</sup>O gas positron emission tomography (PET) and each parameter was obtained in the bilateral middle cerebral artery (MCA) territories. CBF was also obtained using H<sub>2</sub> <sup>15</sup>O PET scanning performed at baseline and at 5, 15, and 30 min after ACZ administration. Relative CBF at each time point after ACZ administration to baseline CBF was calculated. For MCA territories with normal cerebral blood volume (CBV) and cerebral metabolic rate of oxygen (CMRO<sub>2</sub>), CBF continued increasing until 15 min after ACZ administration. For MCA territories with abnormally increased CBV, CBF decreased 5 min after ACZ administration. After that, CBF continued increasing until 30 min after ACZ administration. For MCA territories with abnormally decreased CMRO<sub>2</sub>, CBF did not change 5 min after ACZ administration. Ten min later, CBF increased. The accuracy to detect abnormally increased CBV was significantly greater for relative CBF<sub>5</sub> than for relative CBF<sub>15</sub>. The accuracy to detect abnormally decreased CMRO<sub>2</sub> was significantly greater for relative CBF<sub>5</sub> or CBF<sub>15</sub> than for relative CBF<sub>30</sub>. For detecting abnormally increased oxygen extraction fraction, the accuracy did not differ among each relative CBF. These findings suggested that CBF measurement at 5 min after ACZ administration is the optimal timing for detection of preexisting cerebral hemodynamics and metabolism in bilateral major cerebral artery steno-occlusive diseases.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727876/pdf/ajnmmi0011-0507.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time. 靶向同源二聚体FAP抑制剂的成纤维细胞激活蛋白(FAP)放射治疗:改善肿瘤摄取和保留时间的一步。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Euy Sung Moon, Sanjana Ballal, Madhav Prasad Yadav, Chandrasekhar Bal, Yentl Van Rymenant, Sarah Stephan, An Bracke, Pieter Van der Veken, Ingrid De Meester, Frank Roesch
{"title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time.","authors":"Euy Sung Moon,&nbsp;Sanjana Ballal,&nbsp;Madhav Prasad Yadav,&nbsp;Chandrasekhar Bal,&nbsp;Yentl Van Rymenant,&nbsp;Sarah Stephan,&nbsp;An Bracke,&nbsp;Pieter Van der Veken,&nbsp;Ingrid De Meester,&nbsp;Frank Roesch","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several radiopharmaceuticals targeting fibroblast activation protein (FAP) based on the highly potent FAP inhibitor UAMC1110 are currently under investigation. Pre-clinical as well as clinical research exhibited the potential of these imaging agents. However, the monomeric small molecules seemed to have a short retention time in the tumor in combination with fast renal clearance. Therefore, our strategy was to develop homodimeric systems having two FAP inhibitors to improve residence time and tumor accumulation. The homodimers with two squaramide coupled FAP inhibitor conjugates DOTA.(SA.FAPi)<sub>2</sub> and DOTAGA.(SA.FAPi)<sub>2</sub> were synthesized and radiochemically evaluated with gallium-68. [<sup>68</sup>Ga]Ga-DOTAGA.(SA.FAPi)<sub>2</sub> was tested for its <i>in vitro</i> stability, lipophilicity and affinity properties. In addition, human PET/CT scans were performed for [<sup>68</sup>Ga]Ga-DOTAGA.(SA.FAPi)<sub>2</sub> with a head-to-head comparison with [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi and [<sup>18</sup>F]FDG. Labeling with gallium-68 demonstrated high radiochemical yields. Inhibition measurements revealed excellent affinity and selectivity with low nanomolar IC<sub>50</sub> values for FAP. In PET/CT human studies, significantly higher tumor uptake as well as longer tumor retention could be observed for [<sup>68</sup>Ga]Ga-DOTAGA.(SA.FAPi)<sub>2</sub> compared to [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi. Therefore, the introduction of the dimer led to an advance in human PET imaging indicated by increased tumor accumulation and prolonged retention times <i>in vivo</i> and thus, the use of dimeric structures could be the next step towards prolonged uptake of FAP inhibitors resulting in radiotherapeutic analogs of FAP inhibitors.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727881/pdf/ajnmmi0011-0476.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The use of 68Ga-EDTA PET allows detecting progressive decline of renal function in rats. 使用68Ga-EDTA PET可以检测大鼠肾功能的进行性下降。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Andrea O Fontana, Mary Gonzalez Melo, Gilles Allenbach, Costa Georgantas, Ruijia Wang, Olivier Braissant, Frederic Barbey, John O Prior, Diana Ballhausen, David Viertl
{"title":"The use of <sup>68</sup>Ga-EDTA PET allows detecting progressive decline of renal function in rats.","authors":"Andrea O Fontana,&nbsp;Mary Gonzalez Melo,&nbsp;Gilles Allenbach,&nbsp;Costa Georgantas,&nbsp;Ruijia Wang,&nbsp;Olivier Braissant,&nbsp;Frederic Barbey,&nbsp;John O Prior,&nbsp;Diana Ballhausen,&nbsp;David Viertl","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Introduction: </strong>Evaluation of glomerular filtration rate is very important in both preclinical and clinical setting, especially in the context of chronic kidney disease. It is typically performed using <sup>51</sup>Cr-EDTA or by imaging with <sup>123</sup>I-Hippuran scintigraphy, which has a significantly lower resolution and sensitivity as compared to PET. <sup>68</sup>Ga-EDTA represents a valid alternative due to its quick availability using a <sup>68</sup>Ge/<sup>68</sup>Ga generator, while PET/CT enables both imaging of renal function and accurate quantitation of clearance of activity from both plasma and urine. Therefore, we aimed at investigating the use of <sup>68</sup>Ga-EDTA as a preclinical tracer for determining renal function in a knock-in rat model known to present progressive decline of renal function.</p><p><strong>Methods: </strong><sup>68</sup>Ga-EDTA was injected in 23 rats, either wild type (n=10) or knock-in (n=13). By applying a unidirectional, two-compartment model and Rutland-Patlak Plot linear regression analysis, split renal function was determined from the age of 6 weeks to 12 months.</p><p><strong>Results: </strong>Glomerular filtration ranged from 0.025±0.01 ml/min at 6 weeks to 0.049±0.05 ml/min at 6 months in wild type rats. Glomerular filtration was significantly lower in knock-in rats at 6 and 12 months (P<0.01). No significant difference was observed in renal volumes between knock-in and wild type animals, based on imaging-derived volume calculations.</p><p><strong>Conclusions: </strong><sup>68</sup>Ga-EDTA turned out to be a very promising PET/CT tracer for the evaluation of split renal function. This method allowed detection of progressive renal impairment in a knock-in rat model. Additional validation in a human cohort is warranted to further assess clinical utility in both, healthy individuals and patients with renal impairment.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727875/pdf/ajnmmi0011-0519.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dimeric FAPI with potential for tumor theranostics. 具有肿瘤治疗潜力的二聚 FAPI。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-12-15 eCollection Date: 2021-01-01
Chunxia Qin, Yangmeihui Song, Weibo Cai, Xiaoli Lan
{"title":"Dimeric FAPI with potential for tumor theranostics.","authors":"Chunxia Qin, Yangmeihui Song, Weibo Cai, Xiaoli Lan","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Radionuclide-labeled fibroblast activation protein inhibitors (FAPIs) are popular nuclear imaging probes in recent years. It's of great significance for tumor diagnosis and has great potential in tumor treatment. However, optimization of the probes is needed to further increase tumor uptake and prolong tumor retention for improved treatment efficacy and fewer side effects. In this issue of AJNMMI, Moon et al. reported two squaramide coupled FAPI conjugates (DOTA.(SA.FAPi)<sub>2</sub> and DOTAGA.(SA.FAPi)<sub>2</sub>) and labeled them with <sup>68</sup>Ga. The resulted tracers showed increased tumor accumulation and persistent retention, which led to an advance in PET imaging. The use of dimeric structures provides a feasible strategy to develop radiotherapeutic analogs of FAP inhibitors.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727879/pdf/ajnmmi0011-0537.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39801106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tau-PET imaging as a molecular modality for Alzheimer's disease. Tau-PET成像作为阿尔茨海默病的分子模式。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-10-15 eCollection Date: 2021-01-01
Cyrus Ayubcha, Grant Rigney, Austin J Borja, Thomas Werner, Abass Alavi
{"title":"Tau-PET imaging as a molecular modality for Alzheimer's disease.","authors":"Cyrus Ayubcha,&nbsp;Grant Rigney,&nbsp;Austin J Borja,&nbsp;Thomas Werner,&nbsp;Abass Alavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is the most prevalent neurodegenerative condition. The definitive diagnosis of AD remains a post-mortem neuropathological study of the brain. Unfortunately, there are no established diagnostic criteria to achieve an accurate diagnosis of AD in a similarly objective fashion among living patients. Molecular imaging provides one way of enhancing clinical criteria where objective measures of AD correlate to the presence and progression of disease. In this article, the amyloid and tau hypotheses are considered with respect to pathological, imaging, and therapeutic studies. The value of beta-amyloid (Aβ) PET and tau PET are ascertained. Subsequently, the binding characteristics and quality of Aβ and tau tracers are explored. Finally, the value of Aβ and tau imaging in AD can be determined relevant from in-vivo studies of AD patients. Considering the evolving literature in AD and PET imaging, it has become clear that PET can play a role in the diagnosis and prognosis of AD. The use of Aβ imaging has been extensively studied with mixed results suggesting a limited clinical utility. Conversely, tau-PET has shown early success in similar applications as Aβ imaging. Specifically, we find that there is value in FDG-PET and prospective utility in tau-PET. Ultimately, the community must acknowledge that the role of Aβ imaging for diagnosing and managing AD is very limited and that FDG-PET will remain the study of choice at this time. Moreover, research efforts must continue to determine the prospective value of tau imaging to the assessment of this disease.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569333/pdf/ajnmmi0011-0374.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39711876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementation of FDG-PET/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial. 实施FDG-PET/CT成像方法量化局部晚期非小细胞肺癌患者的炎症反应:来自ACRIN 6668/RTOG 0235试验的结果
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-10-15 eCollection Date: 2021-01-01
Pegah Jahangiri, Alexandra D Dreyfuss, Fenghai Duan, Bradley S Snyder, Austin J Borja, Kamyar Pournazari, Esha Kothekar, Leila Arani, Abdullah Al-Zaghal, Siavash Mehdizadeh Seraj, Emily C Hancin, Benjamin Pinheiro, Thomas J Werner, Samuel Swisher-McClure, Steven J Feigenberg, Drew A Torigian, Mona-Elisabeth Revheim, Charles B Simone, Abass Alavi
{"title":"Implementation of FDG-PET/CT imaging methodology for quantification of inflammatory response in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.","authors":"Pegah Jahangiri,&nbsp;Alexandra D Dreyfuss,&nbsp;Fenghai Duan,&nbsp;Bradley S Snyder,&nbsp;Austin J Borja,&nbsp;Kamyar Pournazari,&nbsp;Esha Kothekar,&nbsp;Leila Arani,&nbsp;Abdullah Al-Zaghal,&nbsp;Siavash Mehdizadeh Seraj,&nbsp;Emily C Hancin,&nbsp;Benjamin Pinheiro,&nbsp;Thomas J Werner,&nbsp;Samuel Swisher-McClure,&nbsp;Steven J Feigenberg,&nbsp;Drew A Torigian,&nbsp;Mona-Elisabeth Revheim,&nbsp;Charles B Simone,&nbsp;Abass Alavi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We measured changes in 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) images in the lung parenchyma to quantify the degree of lung inflammation in patients with locally advanced non-small cell lung cancer (NSCLC) who received radiotherapy (RT). The goal of this study was to demonstrate successful implementation of this imaging methodology on NSCLC patients and to report quantitative statistics between pre-RT and post-RT. Seventy-one patients with NSCLC underwent FDG-PET/CT imaging before and after RT in a prospective study (ACRIN 6668/RTOG 0235). Comparisons between pre-RT and post-RT PET/CT were conducted for partial volume corrected (PVC)-mean standardized uptake value (SUVmean), PVC-global lung parenchymal glycolysis (GLPG), and lung volume for both ipsilateral and contralateral lungs using the nonparametric Wilcoxon signed-rank test. Regression modeling was conducted to associate clinical characteristics with post-RT PET/CT parameters. There was a significant increase in average SUVmean and GLPG of the ipsilateral lung (relative change 40% and 20%) between pre-RT and post-RT PET/CT scans (P<0.0001 and P=0.004). Absolute increases in PVC-SUVmean and PVC-GLPG were more pronounced (ΔPVC-SUVmean 0.32 versus ΔSUVmean 0.28; ΔPVC-GLPG 463.34 cc versus ΔGLPG 352.90 cc) and highly significant (P<0.0001). In contrast, the contralateral lung demonstrated no significant difference between pre-RT to post-RT in either GLPG (P=0.12) or SUVmean (P=0.18). The only clinical feature significantly associated with post-RT PET/CT parameters was clinical staging. Our study demonstrated inflammatory response in the ipsilateral lung of NSCLC patients treated with photon RT, suggesting that PET/CT parameters may serve as biomarkers for radiation pneumonitis (RP).</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569334/pdf/ajnmmi0011-0415.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39711880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Temporary opening of the blood-brain barrier with the nitrone compound OKN-007. 用硝基化合物OKN-007暂时打开血脑屏障。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-10-15 eCollection Date: 2021-01-01
Rheal A Towner, Debra Saunders, Megan Lerner, Robert Silasi Mansat, Tian Yuan, Dylan Barber, Janet Faakye, Adam Nyul-Toth, Anna Csiszar, Beverley Greenwood-Van Meerveld, Nataliya Smith
{"title":"Temporary opening of the blood-brain barrier with the nitrone compound OKN-007.","authors":"Rheal A Towner,&nbsp;Debra Saunders,&nbsp;Megan Lerner,&nbsp;Robert Silasi Mansat,&nbsp;Tian Yuan,&nbsp;Dylan Barber,&nbsp;Janet Faakye,&nbsp;Adam Nyul-Toth,&nbsp;Anna Csiszar,&nbsp;Beverley Greenwood-Van Meerveld,&nbsp;Nataliya Smith","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The blood-brain barrier (BBB) is usually impermeable to several drugs, which hampers treatment of various brain-related diseases/disorders. There have been several approaches to open the BBB, including intracarotid infusion of hyperosmotic concentrations of arabinose, mannitol, oleic or linoleic acids, or alkylglycerols, intravenous infusion of bradykinin B2, administration of a fragment of the ZO toxin from <i>vibrio cholera</i>, targeting specific components of the tight junctions (e.g. claudin-5) with siRNA or novel peptidomimetic drugs, or the use of ultrasound with microbubbles. We propose the use of a low molecular weight (MW), nitrone-type compound, OKN-007, which can temporarily open up the BBB for 1-2 hours. Gadolinium (Gd)-based compounds assessed ranged in MW from 546 (Gd-DTPA) to 465 kDa (β-galactosidase-Gd-DOTA). We also included an albumin-based CA (albumin-Gd-DTPA-biotin) for assessment, as well as an antibody (Ab) against a neuron-specific biomarker conjugated to Gd-DOTA (anti-EphB2-Gd-DOTA). For the anti-EphB2 (goat Ab)-Gd-DOTA assessment, we utilized an anti-goat Ab conjugated with horse radish peroxidase (HRP) for confirmation of the presence of the anti-EphB2-Gd-DOTA probe. In addition, a Cy5 labeled anti-EphB2 Ab was co-administered with the anti-EphB2-Gd-DOTA probe, and assessed <i>ex vivo</i>. This study demonstrates that OKN-007 may be able to temporarily open up the BBB to augment the delivery of various compounds ranging in MW from as small as ~550 to as large as ~470 kDa. This compound is an investigational new drug for glioblastoma (GBM) therapy in clinical trials. The translational capability for human use to augment the delivery of non-BBB-permeable drugs is extremely high.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569329/pdf/ajnmmi0011-0363.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39711875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard. 原发性前列腺癌的定位:FACBC PET/CT与多参数MRI的比较,以组织病理学为参考标准。
IF 2.5
American journal of nuclear medicine and molecular imaging Pub Date : 2021-10-15 eCollection Date: 2021-01-01
Knut Håkon Hole, Andreas Julius Tulipan, Jeroen Sebastiaan Reijnen, Eivor Hernes, Ljiljana Vlatkovic, Agnes Kathrine Lie, Mona-Elisabeth Revheim, Therese Seierstad
{"title":"Localization of primary prostate cancer: FACBC PET/CT compared with multiparametric MRI using histopathology as reference standard.","authors":"Knut Håkon Hole,&nbsp;Andreas Julius Tulipan,&nbsp;Jeroen Sebastiaan Reijnen,&nbsp;Eivor Hernes,&nbsp;Ljiljana Vlatkovic,&nbsp;Agnes Kathrine Lie,&nbsp;Mona-Elisabeth Revheim,&nbsp;Therese Seierstad","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>FACBC (anti-1-amino-3-<sup>18</sup>F-fluorocyclobutane-1-carboxylic acid) is a FDA-approved PET-tracer in patients with suspected recurrent prostate cancer. In the diagnostic work-up of primary prostate cancer, accurate localization of the index tumor is needed for image-guidance of biopsies. We therefore assessed the performance of FACBC PET/CT to detect and localize the index tumor and compared it to multiparametric MRI (mpMRI) using whole-mount histopathology as reference standard. Twenty-three patients with biopsy-proven prostate cancer had FACBC PET/CT and mpMRI within two weeks prior to prostatectomy. FACBC PET/CT was acquired as 14 minutes list-mode and re-binned into seven 2-minutes intervals. Static FACBC was the acquired data from 4-6 minutes, whereas the dynamic FACBC included all seven intervals. Two radiologists and two nuclear medicine physicians independently interpreted the images and consensus was reached in case of discrepancy. Static PET detected 15 of 23 (65%) of the index tumors, dynamic PET detected 14 of 22 (64%), and MRI detected 20 of 23 (87%). To assess the extent of the tumor, the interpreters delineated the tumor in a 12-regions sector-based template. True positive, true negative, false positive and false negative sectors were recorded based on the template drawings and whole-mount histopathology. Both static and dynamic FACBC PET had sensitivity of 40% and specificity of 99%, whereas MRI had sensitivity of 81% and specificity of 100%. Our data indicate that FACBC PET/CT may be useful but that mpMRI is better for localizing the index tumor in patients with prostate cancer.</p>","PeriodicalId":7572,"journal":{"name":"American journal of nuclear medicine and molecular imaging","volume":null,"pages":null},"PeriodicalIF":2.5,"publicationDate":"2021-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8569330/pdf/ajnmmi0011-0387.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39711877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信